🔗 Share this article

Given that America proceeds with sweeping revisions to its vaccine guidelines, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccinations throughout the global health crisis and has focused upon potential deaths after COVID-19 vaccination in her short position at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Schedule

Agency leaders planned to unveil major changes to the childhood vaccination calendar earlier this month, aligning the US with the Danish national calendar, sources say – a significant shift that would place the US at odds with much of the international standard with little proof for improved outcomes. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to present at the meeting. She was recently named interim head of the FDA’s CDER, the fifth person to lead the division this year.

A New Direction at the Agency

The acting appointment could signify a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain childhood immunization guidelines in the US in order to be more similar to the Danish model, a society with comprehensive healthcare and a population approximately the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccines – traditionally the domain of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Background

Høeg has no apparent experience in drug development, oversight or management, which has been standard for past heads of the biologics center. She has served at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a sizeable institution. She has no expertise in industry regulation.”

Past heads of CBER would “grasp laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that former directors who headed CBER have had.”

The drug center has an immense workload at the agency, the former commissioner pointed out.

“The public just focuses on the novel medication approvals, but the generic drug division approves a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one must be managed,” Dr. Woodcock said. “The area you neglect, that is the part that I always told people is going to bite you.”

There is also, a significant management component to the position, which supervises over 5,000 employees. “It is a enormous management job, if you do it right,” the former official added.

Response and Contentious Policies

In response to concerns about Høeg’s qualifications and whether this selection indicates more teamwork among regulatory chiefs on vaccines, a press secretary stated that the “concerns are based on incorrect assumptions”.

“Her resume is consistent with the responsibilities of her role,” the spokesperson explained, noting the months Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s new fast-track approval initiative, a contentious one-day therapy clearance system that allegedly worried her predecessors. “By what process are these drugs being chosen for this voucher program? Who takes the choices?” Howard questioned. “There is a lot of confidentiality going on at the agency right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards less stringent rules of most medications, with the exception of shots.”

Public History on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if concerning, history, critics observe. She published a research paper using unverified public submissions to determine the incidence of heart inflammation after COVID-19 immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the new government encompassed altering regulations for new vaccines and halting “non-essential” vaccines, she said after the election on a audio program. At the agency, Høeg has reportedly suggested excluding young men from obtaining Covid vaccines.

“She is an thorough true believer who commences with her conclusions and reverse-engineers to accommodate the evidence in a extremely deceptive, untruthful fashion,” Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|